Qiagen (QGEN) Competitors $47.76 +0.96 (+2.05%) Closing price 10/8/2025 03:59 PM EasternExtended Trading$47.58 -0.18 (-0.38%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock QGEN vs. TECH, A, DHR, TMO, ONC, INSM, BNTX, TEVA, GMAB, and SMMTShould you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Thermo Fisher Scientific (TMO), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), and Summit Therapeutics (SMMT). These companies are all part of the "medical" sector. Qiagen vs. Its Competitors Bio-Techne Agilent Technologies Danaher Thermo Fisher Scientific BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Bio-Techne (NASDAQ:TECH) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment. Is TECH or QGEN more profitable? Qiagen has a net margin of 18.30% compared to Bio-Techne's net margin of 6.02%. Qiagen's return on equity of 14.77% beat Bio-Techne's return on equity.Company Net Margins Return on Equity Return on Assets Bio-Techne6.02% 13.43% 10.32% Qiagen 18.30%14.77%8.87% Which has higher earnings and valuation, TECH or QGEN? Qiagen has higher revenue and earnings than Bio-Techne. Qiagen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Techne$1.22B7.73$73.40M$0.46131.65Qiagen$1.98B5.37$83.59M$1.6928.26 Do analysts rate TECH or QGEN? Bio-Techne currently has a consensus price target of $70.17, indicating a potential upside of 15.86%. Qiagen has a consensus price target of $49.40, indicating a potential upside of 3.44%. Given Bio-Techne's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bio-Techne is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Techne 1 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.60Qiagen 0 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media prefer TECH or QGEN? In the previous week, Bio-Techne had 2 more articles in the media than Qiagen. MarketBeat recorded 10 mentions for Bio-Techne and 8 mentions for Qiagen. Bio-Techne's average media sentiment score of 0.80 beat Qiagen's score of 0.69 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, TECH or QGEN? Bio-Techne has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Is TECH or QGEN a better dividend stock? Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.5%. Qiagen pays an annual dividend of $0.25 per share and has a dividend yield of 0.5%. Bio-Techne pays out 69.6% of its earnings in the form of a dividend. Qiagen pays out 14.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Do institutionals and insiders believe in TECH or QGEN? 99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryBio-Techne beats Qiagen on 12 of the 19 factors compared between the two stocks. Get Qiagen News Delivered to You Automatically Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QGEN vs. The Competition Export to ExcelMetricQiagenMED IndustryMedical SectorNYSE ExchangeMarket Cap$10.40B$3.35B$6.10B$22.02BDividend Yield0.53%2.28%5.69%3.59%P/E Ratio28.2221.5785.6029.86Price / Sales5.37273.73538.2165.92Price / Cash14.6047.1237.9224.43Price / Book2.9810.1413.244.64Net Income$83.59M-$52.31M$3.30B$1.01B7 Day Performance3.24%5.14%4.35%0.44%1 Month Performance1.44%14.68%9.51%3.13%1 Year Performance10.52%30.98%88.04%15.30% Qiagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QGENQiagen4.3007 of 5 stars$47.76+2.1%$49.40+3.4%+12.8%$10.40B$1.98B28.225,765Analyst ForecastTECHBio-Techne4.7806 of 5 stars$61.92-1.6%$70.42+13.7%-17.9%$9.80B$1.22B134.613,100Analyst UpgradeAAgilent Technologies4.001 of 5 stars$141.64flat$142.17+0.4%-2.6%$40.16B$6.51B33.2517,900Trending NewsAnalyst ForecastDHRDanaher4.9826 of 5 stars$211.65-1.6%$245.91+16.2%-23.7%$153.94B$23.88B45.0363,000Trending NewsAnalyst ForecastTMOThermo Fisher Scientific4.8911 of 5 stars$544.44+0.2%$585.37+7.5%-9.9%$205.16B$42.88B31.49125,000Trending NewsAnalyst ForecastONCBeOne Medicines1.469 of 5 stars$344.53+0.2%$336.30-2.4%N/A$37.69B$3.81B0.0011,000Analyst ForecastINSMInsmed3.2682 of 5 stars$158.28+0.7%$149.06-5.8%+126.7%$33.22B$363.71M-27.721,271Analyst ForecastBNTXBioNTech2.651 of 5 stars$105.16-0.3%$134.56+28.0%-11.7%$25.36B$2.98B-65.726,772Positive NewsTEVATeva Pharmaceutical Industries3.0112 of 5 stars$19.99-0.1%$25.57+27.9%+15.3%$22.95B$16.54B8.0036,830Analyst ForecastAnalyst RevisionGMABGenmab A/S4.3435 of 5 stars$33.31-0.7%$40.80+22.5%+38.8%$21.55B$3.12B19.632,682Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics3.1722 of 5 stars$22.15+3.4%$31.29+41.2%+18.5%$15.92B$700K0.00110Analyst Forecast Related Companies and Tools Related Companies TECH Alternatives A Alternatives DHR Alternatives TMO Alternatives ONC Alternatives INSM Alternatives BNTX Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:QGEN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qiagen N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qiagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
